This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ProMab
product type :
antibody
product name :
Mouse Monoclonal Antibody to LPP
catalog :
20178
quantity :
100µl
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
reactivity :
human, mouse
application :
western blot, ELISA, immunohistochemistry, immunocytochemistry
product information
Catalog :
20178
Title :
Mouse Monoclonal Antibody to LPP
Species :
Human; Mouse; Monkey; Hamster
Clone :
8B3A11;
lsotype :
Mouse IgG1
Size :
100µl
Storage :
4?; -20? for long term storage
Description :
LIM domain containing preferred translocation partner in lipoma. The Zyxin family of proteins contains five members, Ajuba, LIMD1, LPP,TRIP6 and Zyxin. LPP (LIM-containing lipoma-preferred partner), a LIM domain-containing scaffolding protein contains three LIM domains at its carboxy terminus, which are preceded by a proline-rich pre-LIM region containing a number of protein interaction domains. LPP, an 80 kDa protein, localizes to sites of cell adhesion, such as focal adhesions and cell-cell contacts,and shuttles to the nucleus where it has transcriptional activation capacity.The human LPP gene maps to chromosomal location 3q28, and preferentially translocates to the HMGIC gene in a subclass of human benign mesenchymal tumors known as lipomas.
Immunogen :
Purified recombinant fragment of human LPP expressed in E. Coli.
Formulation :
Ascitic fluid containing 0.03% sodium azide.
Applications :
ELISA: 1/10000; WB: 1/500 - 1/2000; IHC: 1/200 - 1/1000; ICC: 1/200 - 1/1000
References :
1. BMC Cell Biol. 2005 Jan 13;6(1):1 ; 2. Mol Cell Proteomics. 2005 Sep;4(9):1240-50. Epub 2005 Jun 11. ; 3. Cancer Genet Cytogenet. 2005 Nov;163(1):68-70. ;
Type :
Monoclonal Antibody
MW :
66kDa
Aliases :
LPP
company information
ProMab
5221 Central Avenue, Suite 200
Richmond, CA 94804
Richmond, CA 94804
info@promab.com
http://www.promab.com1-866-339-0871
headquarters: USA
questions and comments